Ocular Therapeutix公司 OCUL 深 滬
等待開盤 04-17 09:30:00 美东时间
8.86
-0.050
-0.56%
華盛通- 最 高8.93
- 今 開8.91
- 成交量 201.84万股
- 最 低 8.69
- 昨 收 8.91
- 總市值 19.29亿
- 52周最高 16.44
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 6.2301
- 委 比 -82.00%
- 總股本 2.18亿
- 歷史最高 44.19
- 量 比 0.62
- 振 幅 2.69%
- 歷史最低 1.995
- 每 手 1
- 風險率 1.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study
Ocular Therapeutix shares up on positive data for wet AMD treatment. Company focusing on retinal diseases and on track for FDA submission.
04-14 01:31
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $21 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $21 price target.
04-14 00:59
Ocular Therapeutix Reports One-Year Results For Eye Disease Treatment
Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), an integrated biopharmaceutical company committed to redefining the retina experience, today announced additional positive Week 52 data from the SOL-1 Phase 3
04-13 19:08
Ocular Therapeutix to present additional SOL-1 Phase 3 AXPAXLI data at April conferences
Ocular Therapeutix to present additional SOL-1 Phase 3 AXPAXLI data at April conferences Ocular Therapeutix will present additional SOL-1 Phase 3 superiority trial data and analyses for AXPAXLI (OTX-TKI) in wet age-related macular degeneration at Vit-Buckle Society annual meeting on April 9-11, 2026
04-01 19:07
EyePoint Files Lawsuit Against Ocular Therapeutix Alleging Defamation And Misleading Claims Over DURAVYU Clinical Results
On March 20, 2026, EyePoint, Inc. (the "Company") filed a complaint against Ocular Therapeutix, Inc. (the "Defendant") in the Middlesex County Superior Court for the Commonwealth of Massachusetts (the "Complaint"). The
03-21 04:39
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raised to $28, MDB cut to $260, RIOT cut to $23, DAVE raised to $295, NTST raised to $22, U raised to $19, TREE cut to $290.
03-03 21:37
Clear Street Maintains Buy on Ocular Therapeutix, Raises Price Target to $28
Clear Street analyst Bill Maughan maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $28.
03-03 18:06
美股牛股 | 英伟达40亿美元押注光通信！应用光电大涨超21%；BATL暴涨超113%
英伟达40亿美元押注光通信！应用光电大涨超21%；美伊冲突点燃“油气”市场，BATL股价暴涨超113%>>
03-03 16:03
